Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHRINK: NKR-2 + FOLFOX in Colorectal Cancer Liver Metastases
NCT03310008Phase 1Unknown
- Sponsor
- Celyad Oncology
- Start
- Aug 2017
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-NKG2D in colorectal cancer (CRC) (4 arms), sponsored by Celyad Oncology. Primary endpoints: Dose Limiting Toxicities and Objective Response Rate. Status: unknown.
02
Drugs
CAR-NKG2D
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03310008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310008.